Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...
15h
Daily Express US on MSNOzempic and Zepbound linked to rare eye conditions that could cause blindnessA new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...
Blockbuster GLP-1 medications like Ozempic and Mounjaro might sharpen your figure, but they could also cloud your vision in ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...
WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results